Differentiated
CNS therapeutics.
Novel small-molecule medicines.
A focused path from discovery to development.
Our perspective
Original chemistry.
Clinical perspective.
Focused development.
We bring medicinal chemistry, neuroscience and clinical development together to pursue new possibilities in CNS medicine.
Our lead neuroplastogen program, TL-01, is advancing through lead optimization. Its indication and detailed development strategy remain proprietary as the program progresses.
Meet the teamThe portfolio
A lead program.
A broader discovery effort.
TL-01Lead program
Our lead neuroplastogen
In lead optimization for a proprietary CNS indication. Indication details remain in stealth.
Preclinical developmentTL-02 — TL-06Discovery programsHit identification & synthesis
All programs are investigational. Safety and effectiveness have not been established.
People behind the work
Built around the
work of development.
A founding team spanning discovery chemistry, clinical development, and company building—supported by experienced CNS scientific advisors.
Uroš Laban, PhDCo-Founder & CSO
Tanya Ramey, MD, PhDCo-Founder & CMO
Graham PilgerCo-Founder & CEO